Development of a cell line system susceptible to infection with vaccine strains of MDV.
Despite reliance on the need to continually prepare fresh cultures of chick embryo fibroblasts (CEFs) to make Marek's disease (MD) vaccines, MD vaccines are the most widely used vaccines in the poultry industry. Preparation of CEF's accounts for approximately 40% of the costs associated with producing MD vaccines. A significant reduction in MD vaccine production costs could be realized if a continuous cell lines were available for MD vaccine production. Recently, we reported development and characterization of a cell line system (OCL) that supports growth and replication of oncogenic serotype 1 Marek's disease virus (MDV). Here we report development of three cell line systems for production of MD vaccine. These cell lines support the growth and replication of attenuated serotype 1 MDV (CVI-OCL), serotype 2 MDV (SB1-OCL) and serotype 3 MDV (HVT-OCL). MDV is maintained in a stable state in the OCL cells and the infected cells can be continuously grown. The vaccines made from these cell lines are safe and protect White Leghorn chickens against challenge with very virulent serotype 1 MDV, similar to traditional vaccines made from CEF cells. These cell line systems can significantly reduce the costs associated with MD vaccine production. Furthermore, the increased stability of MDV and the potential for positive selection of recombinant MDV suggest that OCL will be ideal for production of more effective MDV vaccines using recombinant DNA technology.
Abujoub
A A
AA
Origen Inc., Molecular Virology Division, Lansing, MI 48910, USA. abujouba@pilot.msu.edu
Williams
D L
DL
Reilly
J D
JD
D000818:Animals; D002460:Cell Line; D002478:Cells, Cultured; D002642:Chick Embryo; D002645:Chickens; D005347:Fibroblasts; D018142:Gammaherpesvirinae / Q000254:growth & development* / Q000276:immunology*; D008381:Herpesvirus 2, Gallid / Q000254:growth & development* / Q000276:immunology*; D008380:Marek Disease / Q000517:prevention & control; D014422:Turkeys / Q000821:virology; D010948:Viral Plaque Assay; D014765:Viral Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D014776:Virus Cultivation
D014765:Viral Vaccines